The weight loss medicines are proving to be a test case for Robert F. Kennedy Jr., the health secretary, in straddling divisions between his supporters and the president.
Kennedy Walks a Tightrope on Trump Deal for Obesity Drugs
Written by
in
Diabetes, Diet and Nutrition, Drugs (Pharmaceuticals), Eli Lilly and Company, Food and Drug Administration, GLP-1 RAs (Drug), Health and Human Services Department, Health Insurance and Managed Care, Kennedy, Robert F Jr, Medicare, Novo Nordisk A/S, Ozempic (Drug), Prices (Fares, Fees and Rates), Regulation and Deregulation of Industry, Trump, Donald J, United States Politics and Government